Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Female

The purpose of this study is to investigate the optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia in female who are reversed with sugammadex or neostigmine.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gallbladder Diseases Biliary Tract Diseases Digestive System Diseases

Age range

19 year–60 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine

Suwon, Gyeonggido, 16499, South Korea

About this study

Remifentanil is a potent ultrashort-acting opioid, with rapid onset and offset of drug effect. It allows rapid anesthetic emergence even after a prolonged infusion, and decreases the at-risk time during extubation. In addition, cough suppression of remifentanil enables smooth extubation with reduced complications. However, the infusion of remifentanil suppresses the emergence cough effectively in clinical practice, whereas it still delays the awakening from anesthesia, resulting in prolonged emergence time. Reduced Ce of remifentanil during emergence would decrease the adverse events that are associated with remifentanil infusion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Laparoscopic cholecystectomy under general anesthesia

Exclusion criteria

BMI > 30 kg/m2, respiratory infection, uncontrolled hypertension

Treatment and study plan

Sugammadex Injectable Product

Drug

Sugammadex of 2 mg/kg is injected.

Neostigmine Injectable Product

Drug

Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.

Primary outcomes

optimal Ce of remifentanil

Time frame: from the ene of surgery until endotracheal extubation

Using Dixon methods, evaluating of optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia

Sponsors and collaborators

Lead sponsor

Ajou University School of Medicine

Other

Registry information

Official study title

Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine

Important dates

Study start: 2019
Primary completion: 2021
Study completion: 2021
First posted: May 29, 2020
Registry last updated: Jan 8, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed